[Skip to Content]
[Skip to Content Landing]
Views 2,059
Citations 0
Editorial
June 2018

Helping Colorectal Cancer Survivors Benefit From Changing Lifestyle BehaviorsImplementation Science and Private Industry Collaboration to the Rescue

Author Affiliations
  • 1Medical Oncology and Genetics, AIM Specialty Health, Chicago, Illinois
  • 2Department of General Oncology, University of Texas MD Anderson Cancer Center, Houston
  • 3Center for Community-Engaged Translational Research, Department of Health Disparities Research, University of Texas MD Anderson Cancer Center, Houston
  • 4Department of Behavioral Science, Center for Energy Balance in Cancer Prevention and Survivorship, University of Texas MD Anderson Cancer Center, Houston
JAMA Oncol. 2018;4(6):777-778. doi:10.1001/jamaoncol.2018.0124

About 20 years ago, investigators working in the National Cancer Institute (NCI) cooperative group system sought to prove that a novel adjuvant therapy regimen would extend the overall survival of patients with stage III colorectal cancer. The CALGB 89803 study compared weekly administration of irinotecan plus fluorouracil and leucovorin vs the standard care at the time, fluorouracil plus leucovorin. Unfortunately, this trial had negative results, and the investigational arm was far more toxic than the standard care.1 The report by Van Blarigan et al2 represents a cancer control gem that came out of the ashes of this trial.

×